THTX - Theratechnologies Inc.

THTX - Theratechnologies Inc.

https://www.theratech.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak - Theratechnologies ( NASDAQ:THTX )

Benzinga • 3 days ago • score: 0.28

MONTREAL, Sept. 12, 2025 ( GLOBE NEWSWIRE ) -- Theratechnologies Inc. ( "Theratechnologies" or the "Company" ) TH THTX, a commercial-stage biopharmaceutical company, is pleased to announce that its shareholders have approved the previously announced plan of arrangement ( the "Arrangement" ) ...

Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak

GlobeNewswire • 3 days ago • score: 0.31

MONTREAL, Sept. 12, 2025 ( GLOBE NEWSWIRE ) -- Theratechnologies Inc. ( "Theratechnologies" or the "Company" ) ( TSX: TH ) ( NASDAQ: THTX ) , a commercial-stage biopharmaceutical company, is pleased to announce that its shareholders have approved the previously announced plan of arrangement ( ...

Theratechnologies to Announce Second Quarter 2025 Financial Results

GlobeNewswire • 2 months, 1 week ago • score: 0.45

MONTREAL, July 03, 2025 ( GLOBE NEWSWIRE ) -- Theratechnologies Inc. ( "Theratechnologies" or the "Company" ) ( TSX: TH ) ( NASDAQ: THTX ) , a commercial-stage biopharmaceutical company, today announced the Company will report financial results for its second quarter 2025 ended May 31 on ...

Theratechnologies to Announce Second Quarter 2025 Financial Results - Theratechnologies ( NASDAQ:THTX )

Benzinga • 2 months, 1 week ago • score: 0.43

MONTREAL, July 03, 2025 ( GLOBE NEWSWIRE ) -- Theratechnologies Inc. ( "Theratechnologies" or the "Company" ) TH THTX, a commercial-stage biopharmaceutical company, today announced the Company will report financial results for its second quarter 2025 ended May 31 on Wednesday, July 9, 2025.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Theratechnologies Inc., a biopharmaceutical company, is focused on the development and commercialization of various therapies to address unmet medical needs in the United States, Canada, and Europe. The company is headquartered in Montreal, Canada.

52W High

$3.28

52W Low

$1.12

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.81

Valuation

Rich

As of 2025-05-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

55.87

EV/EBITDA (<8 favorable)

76.00

EV/Revenue (<3 favorable)

2.19

P/S (TTM) (<3 favorable)

1.79

P/B (<3 favorable)

20.13

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

1.15%

Institutions (25–75% balanced)

45.49%

Shares Outstanding

45,980,000

Float

38,229,200

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-05-31 (Overview)

Revenue (TTM)

84,378,000

Gross Profit (TTM)

65,579,000

EPS (TTM)

-0.19

Profit Margin (>10% good)

-0.11%

Operating Margin (TTM) (higher better)

-0.11%

ROE (TTM) (>15% strong)

-11.17%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.20

Momentum

Bearish momentum

Value

0.0406

Previous

0.0394

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025